The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Tyrosine kinase inhibitors: From rational design to clinical trials
Abstract
Protein kinases play a crucial role in signal transduction as well as in cellular proliferation, differentiation, and various regulatory mechanisms. The inhibition of growth related kinases, especially tyrosine kinases, might provide new therapies for diseases such as cancer. The progress made in the crystallization of protein kinases has confirmed that the ATP‐binding domain of tyrosine kinases is an attractive target for drug design. Three successful examples of drug design at Novartis using a tyrosine kinase as a molecular target are described. PKI166, a pyrrolo[2,3,‐d]pyrimidine derivative, is a dual inhibitor of both the EGFR and the ErbB2 kinases. The compound entered clinical trials in 1999, based on its favorable preclinical profile: potent inhibition of EGF‐mediated signalling in cells, in vivo antitumor activity in several EGFR overexpressing xenograft tumor models in nude mice, long‐lasting inhibition of EGF‐stimulated EGFR autophosphorylation in tumor tissue, good oral bioavailability in animals, and no prohibitive in vitro and in vivo toxicity findings. The anilino‐phthalazine derivative PTK787/ZK222584 (Phase I, co‐developed by Schering AG, Berlin) is a potent and selective inhibitor of both the KDR and Flt‐1 kinases with interesting anti‐angiogenic and pharmacokinetic properties (orally bioavailable). STI571 (Glivec™, Gleevec™), a phenylamino‐pyrimidine derivative, is a potent inhibitor of the Abl tyrosine kinase, which is present in 95% of patients with chronic myelogenous leukemia (CML). The compound specifically inhibits proliferation of v‐Abl and Bcr‐Abl expressing cells (including cells from CML patients) and shows anti‐tumor activity as a single agent in animal models at well‐tolerated doses. Pharmacologically relevant concentrations are achieved in the plasma of animals (oral administration). Promising data from phase I and II clinical trials in CML patients (98% haematological response rate in Phase I) support the fact that the STI571 represents a new treatment modality for CML. In addition, potent inhibition of the PDGFR and c‐Kit tyrosine kinases also indicates its possible clinical use in solid tumors. © 2001 John Wiley & Sons, Inc. Med Res Rev, 21, No. 6, 499–512, 2001
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationCancer: Principles and Practice of Oncology
Gunn, W. G. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510350091047 · Cited by 1,791
Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Self-citationHeinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Self-citationFong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,026
Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 845
Self-citationBindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843
Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., & Druker, B. J. (1997) · Blood · doi:10.1182/blood.v90.12.4947 · Cited by 554
Self-citationBruns, C. J., Solórzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R. Z., Fan, D., Abbruzzese, J. L., Traxler, P. M., Buchdunger, E., Radinsky, R., et al. (2000) · PubMed · Cited by 532
Self-citationRude Voldborg, B., Damstrup, L., Spang-Thomsen, M., & Skovgaard Poulsen, H. (1997) · Annals of Oncology · doi:10.1023/a:1008209720526 · Cited by 528
Sun, L., Tran, N., Tang, F., App, H., Hirth, P., McMahon, G., & Tang, C. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980123i · Cited by 489
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
Deininger, M. W. N., Goldman, J. M., Lydon, N., & Melo, J. V. (1997) · Blood · doi:10.1182/blood.v90.9.3691 · Cited by 482
Pollack, V. A., Savage, D. M., Baker, D. A., Tsaparikos, K. E., Sloan, D. E., Moyer, J. D., Barbacci, E. G., Pustilnik, L. R., Smolarek, T. A., Davis, J. A., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35162-6 · Cited by 434
In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor
le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., Formelli, F., & Gambacorti-Passerini, C. (1999) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/91.2.163 · Cited by 374
Self-citationGambacorti-Passerini, C., le Coutre, P., Mologni, L., Fanelli, M., Bertazzoli, C., Marchesi, E., Di Nicola, M., Biondi, A., Corneo, G. M., Belotti, D., et al. (1997) · Blood Cells, Molecules, and Diseases · doi:10.1006/bcmd.1997.0155 · Cited by 316
Thiesing, J. T., Ohno-Jones, S., Kolibaba, K. S., & Druker, B. J. (2000) · Blood · doi:10.1182/blood.v96.9.3195 · Cited by 309
Smaill, J. B., Rewcastle, G. W., Loo, J. A., Greis, K. D., Chan, O. H., Reyner, E. L., Lipka, E., Showalter, H. D. H., Vincent, P. W., Elliott, W. L., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990482t · Cited by 269
Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives
Zimmermann, J., Buchdunger, E., Mett, H., Meyer, T., & Lydon, N. B. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(96)00601-4 · Cited by 247
Self-citationBold, G., Altmann, K.-H., Frei, J., Lang, M., Manley, P. W., Traxler, P., Wietfeld, B., Brüggen, J., Buchdunger, E., Cozens, R., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909443 · Cited by 217
Self-citationTraxler, P., Bold, G., Frei, J., Lang, M., Lydon, N., Mett, H., Buchdunger, E., Meyer, T., Mueller, M., & Furet, P. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970124v · Cited by 203
Self-citationVascular endothelial growth factor
Ferrara, N. (1993) · Trends in Cardiovascular Medicine · doi:10.1016/1050-1738(93)90046-9 · Cited by 188
Beran, M., Cao, X., Estrov, Z., Jeha, S., Jin, G., O'Brien, S. M., Talpaz, M., Arlinghaus, R. B., Lydon, N., & Kantarjian, H. M. (1998) · PubMed · Cited by 176
Abl tyrosine kinase in signal transduction and cell-cycle regulation
Wang, J. Y. J. (1993) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(05)80338-7 · Cited by 174
The role of vascular endothelial growth factor in blood vessel formation
Breier, G., & Risau, W. (1996) · Trends in Cell Biology · doi:10.1016/0962-8924(96)84935-x · Cited by 159
Yano, S., Herbst, R. S., Shinohara, H., Knighton, B., Bucana, C. D., Killion, J. J., Wood, J. M., & Fidler, I. J. (2000) · PubMed · Cited by 151
Self-citationZimmermann, J., Buchdunger, E., Mett, H., Meyer, T., Lydon, N., & Traxler, P. M. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00197-7 · Cited by 150
Self-citationRegulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis
Kölch, W., Martiny‐Baron, G., Kieser, A., & Marm�, D. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00666036 · Cited by 142
Dan, S., Naito, M., & Tsuruo, T. (1998) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400400 · Cited by 126
Rewcastle, G. W., Palmer, B. D., Thompson, A. M., Bridges, A. J., Cody, D. R., Zhou, H., Fry, D. W., McMichael, A., & Denny, W. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9508651 · Cited by 114
Rewcastle, G. W., Murray, D. K., Elliott, W. L., Fry, D. W., Howard, C. T., Nelson, J. M., Roberts, B. J., Vincent, P. W., Showalter, H. D. H., Winters, R. T., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970641d · Cited by 113
Furet, P., Caravatti, G., Lydon, N., Priestle, J. P., Sowadski, J. M., Trinks, U. P., & Traxler, P. M. (1995) · Journal of Computer-Aided Molecular Design · doi:10.1007/bf00124317 · Cited by 108
Self-citationRewcastle, G. W., Bridges, A. J., Fry, D. W., Rubin, J. R., & Denny, W. A. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960879m · Cited by 100
Strawn, L. M., & Shawver, L. K. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.4.553 · Cited by 79
Zimmermann, J., Caravatti, G., Mett, H., Meyer, T., Müller, M., Lydon, N., & Fabbro, D. (1996) · Archiv der Pharmazie · doi:10.1002/ardp.19963290707 · Cited by 77
Self-citationTyrosine kinase inhibitors in cancer treatment (Part II)
Traxler, P. M. (1998) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.8.12.1599 · Cited by 68
Self-citationShowalter, H. D., & Kraker, A. J. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00097-1 · Cited by 34
Protein kinase inhibitors: structural determinants for target specificity.
McMahon, G., Sun, L., Liang, C., & Tang, C. (1998) · PubMed · Cited by 32
Cited by
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Intrinsic Disorder in Cell-signaling and Cancer-associated Proteins
Iakoucheva, L. M., Brown, C. J., Lawson, J. D., Obradović, Z., & Dunker, A. K. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00969-5 · Cited by 1,214
Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 950
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
Goldman, J. M., & Melo, J. V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020777 · Cited by 950
Metadata
- Authors
- Traxler, P., Bold, G., Buchdunger, E., Caravatti, G., Furet, P., Manley, P., O'Reilly, T., Wood, J., & Zimmermann, J.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2001-10-05
- Volume
- 21
- Issue
- 6
- Pages
- 499-512
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W1988506250
- Cited by
- 324
- References
- 38
- FWCI
- 23.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.